Latest Insights - page 24 | BiopharmaTrend

Aging-Focused BioAge Posts Q2 2025 Results: Advances Metabolic Pipeline and Expands Longevity Data Platform

BioAge Labs reported second-quarter 2025 results alongside updates on its metabolic disease pipeline and human aging data platform. The company is advancing its oral NLRP3 inhibitor toward Phase 1 testing …

Continue ›››

Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Strand Therapeutics has closed a $153 million Series B financing led by Swedish investment firm Kinnevik, joined by Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, and …

Continue ›››

From Data to Discovery: How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

XtalPi And DoveTree Finalize $6B AI Drug Discovery Agreement

XtalPi has signed a definitive agreement with DoveTree Medicines for an AI- and robotics-powered drug discovery collaboration valued at up to $5.99 billion. The deal builds on the companies’ June …

Continue ›››

Building the Virtual Cell: AI Foundation Models and Billion-Cell Datasets

From early 2000s and a 2012 milestone to a decade-long quiet—virtual cell modeling is resurging with transformers, perturbation atlases, and lab-in-the-loop systems While the term “virtual cell” initially goes back …

Continue ›››

Chai Discovery Raises $70M to Expand Zero-Shot Biologics Design AI Platform

Chai Discovery, an AI drug discovery company founded in late 2024 and backed by OpenAI, has raised $70 million in new funding to expand development of its antibody and molecular …

Continue ›››

WVU Cancer Institute Adopts Ryght AI Tools for Trial Matching and Enrollment

West Virginia University (WVU) Cancer Institute has joined Ryght AI’s clinical trial site network, giving the academic cancer center access to tools designed to automate site feasibility and trial enrollment …

Continue ›››

NIH Foundation Launches Industry-Backed Program to Advance Non-Animal Testing Methods Toward Regulatory Use

The Foundation for the National Institutes of Health (FNIH) has launched the Validation and Qualification Network (VQN), a multi-stakeholder initiative aimed at accelerating the regulatory acceptance of alternatives to animal …

Continue ›››

Recursion Reports Q2 2025 with $7M Sanofi Milestone, Announces Clinical Updates

Recursion Pharmaceuticals, a clinical-stage TechBio company headquartered in Salt Lake City, a founding member of BioHive, Utah’s life sciences collective, reported Q2 2025 financials with a net loss of $171.9 …

Continue ›››

Lantern Pharma Launches AI Platform for Blood-Brain Barrier Permeability Prediction, Completes Japan Trial Enrollment

Lantern Pharma has announced two major milestones: completion of patient enrollment in Japan for its Phase 2 HARMONIC trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC), and …

Continue ›››

Ultromics Gets $55M to Spot Hidden Heart Failure with AI Ultrasound

Oxford-based Ultromics has secured $55 million in Series C funding to expand deployment of its AI-powered echocardiography software across the U.S. and globally. The company develops FDA-cleared tools that analyze …

Continue ›››

Synchron Becomes First to Achieve Native Thought-Control of Apple iPad Using Brain-Computer Interface

The New York-based medtech Synchron, a brain-computer interface (BCI) company backed by DARPA, Gates Frontier, and Bezos Expeditions, has become the first to publicly demonstrate native thought-based control of an …

Continue ›››